Healthcare | May 05, 2026
OBESITAS 2026 concludes with focus on India’s rising obesity burden
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The company announced positive topline data from the Phase II ZUPREME-1 trial
Subscribe To Our Newsletter & Stay Updated
